Nature Communications (Apr 2022)
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma
- Jeppe Sejerø Holm,
- Samuel A. Funt,
- Annie Borch,
- Kamilla Kjærgaard Munk,
- Anne-Mette Bjerregaard,
- James L. Reading,
- Colleen Maher,
- Ashley Regazzi,
- Phillip Wong,
- Hikmat Al-Ahmadie,
- Gopa Iyer,
- Tripti Tamhane,
- Amalie Kai Bentzen,
- Nana Overgaard Herschend,
- Susan De Wolf,
- Alexandra Snyder,
- Taha Merghoub,
- Jedd D. Wolchok,
- Morten Nielsen,
- Jonathan E. Rosenberg,
- Dean F. Bajorin,
- Sine Reker Hadrup
Affiliations
- Jeppe Sejerø Holm
- Experimental and Translational Immunology, Health Technology, Technical University of Denmark
- Samuel A. Funt
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Annie Borch
- Experimental and Translational Immunology, Health Technology, Technical University of Denmark
- Kamilla Kjærgaard Munk
- Experimental and Translational Immunology, Health Technology, Technical University of Denmark
- Anne-Mette Bjerregaard
- Experimental and Translational Immunology, Health Technology, Technical University of Denmark
- James L. Reading
- Cancer Immunology Unit, Research Department of Hematology and Cancer Research UK, Lung Cancer Centre of Excellence, University College London Cancer Institute
- Colleen Maher
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Ashley Regazzi
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Phillip Wong
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Hikmat Al-Ahmadie
- Department of Pathology, Memorial Sloan Kettering Cancer Center
- Gopa Iyer
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Tripti Tamhane
- Experimental and Translational Immunology, Health Technology, Technical University of Denmark
- Amalie Kai Bentzen
- Experimental and Translational Immunology, Health Technology, Technical University of Denmark
- Nana Overgaard Herschend
- Experimental and Translational Immunology, Health Technology, Technical University of Denmark
- Susan De Wolf
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Alexandra Snyder
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Taha Merghoub
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Jedd D. Wolchok
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Morten Nielsen
- Section of Bioinformatics, Health Technology, Technical University of Denmark
- Jonathan E. Rosenberg
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Dean F. Bajorin
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Sine Reker Hadrup
- Experimental and Translational Immunology, Health Technology, Technical University of Denmark
- DOI
- https://doi.org/10.1038/s41467-022-29342-0
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 17
Abstract
Immune checkpoint blockade therapy is successful in a high proportion of cancer patients, but others remain unresponsive. Authors here show that therapeutic success might be predictable in metastatic bladder cancer by longitudinal analysis of the early neoantigen-specific CD8 T cell response in peripheral blood.
